Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Monte Rosa Therapeutics, Inc. Common Stock

Monte Rosa Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies.

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.

RTW Investments

Cormorant Asset Management

Fidelity

Google Ventures

New Enterprise Associates

Cambridge Asset Management

Casdin Capital

HBM Healthcare Investments AG

Fidelity Management and Research Company

Aisling Capital

Amzak Health Investors

Avoro Capital Advisors

Today we share our second quarter 2024 financial results and corporate update. View the full press release here: https://bit.ly/3WDjih9

Step into the future with Monte Rosa's dynamic Data Sciences team! #DataSciences #AI #Biotech

We’re pleased to share this brand new scientific review of VAV1 published in Trends in Immunology, highlighting the therapeutic potential of novel approaches targeting VAV1 for autoimmune diseases, including our VAV1 molecular glue degrader MRT-6160. 

Read the scientific review here: https://bit.ly/4c6BO6Z

Every year Monte Rosa welcomes the brilliant scientists of tomorrow. Their curiosity, innovation, and enthusiasm help shape our culture. Learn more about the Monte Rosa Internship experience. #NationalInternDay #Biotech

Starting off the summer with good times and great people. 
#Summer #GoodTimes

Join our CEO Markus Warmuth next week for a fireside chat at the virtual UBS TPD day. Learn more here: https://bit.ly/3zuVS5I

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-7.74M -	-35.88M 363.55%	-73.96M 106.13%	-108.50M 46.71%	-135.35M 24.75%
depreciation and amortization	72K -	537K 645.83%	2.13M 297.02%	3.75M 75.66%	6.22M 66.14%
deferred income tax			17K -		-5.76M -
stock based compensation		354K -	5.20M 1,368.93%	11.66M 124.31%	16.67M 42.91%
change in working capital	1.77M -	4.25M 140.26%	6.29M 47.73%	-2.13M 133.95%	72.47M 3,495.78%
accounts receivables				-187 -
inventory				187 -
accounts payables	2.86M -	3.44M 20.10%	-706K 120.55%	-744K 5.38%	5.76M 873.92%
other working capital	-1.09M -	820K 175.30%	6.99M 752.68%	-1.39M 119.88%	66.71M 4,899.14%
other non cash items	-276K -	7.68M 2,882.61%	960K 87.50%	2.76M 187.50%	1.95M 29.31%
net cash provided by operating activities	-6.17M -	-23.05M 273.45%	-59.36M 157.51%	-92.47M 55.76%	-43.80M 52.63%
investments in property plant and equipment	-1.39M -	-3.39M 144.69%	-9.73M 187.16%	-12.91M 32.67%	-19.04M 47.48%
acquisitions net			79K -	109K 37.97%	62K 43.12%
purchases of investments				-384.42M -	-103.15M 73.17%
sales maturities of investments				178M -	210.93M 18.50%
other investing activites
net cash used for investing activites	-1.39M -	-3.39M 144.69%	-9.65M 184.83%	-219.22M 2,170.99%	88.80M 140.51%
debt repayment
common stock issued	14.25M -	60.06M 321.47%	237.75M 295.85%	20.05M 91.56%	27.49M 37.08%
common stock repurchased		-440K -
dividends paid
other financing activites	750K -	440K 41.33%	139.81M 31,675.45%	411K 99.71%
net cash used provided by financing activities	15M -	60.06M 300.40%	377.56M 528.64%	20.47M 94.58%	27.49M 34.33%
effect of forex changes on cash					-262K -
net change in cash	7.44M -	33.62M 351.73%	308.55M 817.80%	-291.22M 194.38%	72.23M 124.80%
cash at beginning of period	1.80M -	9.24M 412.76%	42.86M 363.63%	351.41M 719.84%	55.87M 84.10%
cash at end of period	9.24M -	42.86M 363.63%	351.41M 719.84%	60.19M 82.87%	128.10M 112.83%
operating cash flow	-6.17M -	-23.05M 273.45%	-59.36M 157.51%	-92.47M 55.76%	-43.80M 52.63%
capital expenditure	-1.39M -	-3.39M 144.69%	-9.73M 187.16%	-12.91M 32.67%	-19.04M 47.48%
free cash flow	-7.56M -	-26.44M 249.85%	-69.09M 161.31%	-105.38M 52.51%	-62.84M 40.36%

COM:MONTEROSATX

Monte Rosa Therapeutics

Last Close

8.36

21/11 21:00

Market Cap

513.00M

Beta: -

Volume Today

741.95K

Avg: -

Preview